Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients
Fumie Akasaka-Kihara, Daisuke Sueta, Masanobu Ishii, Yuji Maki, Kyoko Hirakawa, Noriaki Tabata, Miwa Ito, Kenshi Yamanaga, Koichiro Fujisue, Tadashi Hoshiyama, Shinsuke Hanatani, Hisanori Kanazawa, Seiji Takashio, Yuichiro Arima, Satoshi Araki, Hiroki Usuku, Taishi Nakamura, Satoru Suzuki, Eiichiro Yamamoto, Hirofumi Soejima, Koichi Kaikita, Kenichi Matsushita, Masao Matsuoka, Koichiro Usuku, Kenichi Tsujita
Abstract
Background: Although the Khorana venous thromboembolism (VTE) risk score (KRS) is well recognized as a simple VTE risk assessment method in patients with cancer, whether it is suitable for Asian populations is unclear. Objectives: This study validated KRS for the prediction of VTE and investigated the value of the KRS in predicting mortality in Japanese patients with cancer. Methods: or more was defined as obesity according to World Health Organization consensus. A total of 27,687 patients with cancer were subdivided into low- (0), intermediate- (1-2), and high-score (3) groups by the KRS. The primary and secondary endpoints were VTE and all-cause mortality, respectively. Results: < 0.01). Conclusions: The KRS was useful in Japanese patients with cancer and might be a potentially useful marker for the prediction of mortality. Establishing optimal scores for Japanese subjects is mandatory because of its low diagnostic ability. (KUMAMON Cancer registry; UMIN000047554).